Stock screenerAll disclosures →
EDGAR →
ZYME
Conviction 51HealthcareScan · Mon, Aug 10, 2026ZYME$24.18+2.70%
ResistanceSupportVol 14Vol MA14 437.73K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price24.18
Change+2.70%
Gap+1.04%
Rel volume1.99×
Avg volume432.71K
Avg $ vol10.12M
SMA 2023.30
SMA 5023.99
SMA 20024.13
Price vs 50+0.77%
Price vs 200+0.20%
MA stackmixed
50/200 crossdeath · 2d
Supertrenddown · 24.65
RSI (14)54
MACD hist0.15
MACD crossbull · 2d
Stoch %K / %D82 / 66
ADX (14)21
+DI / −DI22 / 17
RSI divergence—
MACD divergence—
ATR %+4.25%
ADR %3.85%
52w high28.56
52w low12.02
From 52w high-15.35%
Above 52w low+101.12%
New 52w highNo
SqueezeOff
Bollinger width14.41%
%B0.76
Donchian pos71.76%
Donchian high25.22
Donchian low21.52
AVWAP (52w high)24.62
vs AVWAP high-1.80%
AVWAP (52w low)22.65
vs AVWAP low+6.75%
OBV trendFlat
Chaikin MF (20)-0.27
Today vs 20d1.99×
Avg vol (14d)437.73K
Avg vol (20d)432.71K
Avg $ vol (20d)10.12M
Market cap1.72B
RS 3m (vs SPY)-17.20%
RS 6m (vs SPY)-7.21%
RS line new highNo
Trend template5/8
Technical rank48.0
1 week+10.84%
1 month-6.59%
3 months+1.19%
6 months+6.40%
1 year+98.81%
YTD-9.18%
P/E-21.14
P/B21.34
P/S16.19
P/FCF-49.69
EPS-1.08
Div yield—
ROE-100.95%
ROA-20.44%
Debt/Eq—
Current6.32
EV/EBITDA—
Gross margin—
Net margin-76.56%
Rev growth38.87%
EPS growth33.88%
Price target40.33
Target upside66.83%
Analyst ratingBuy
Institutional101.91%
Ent. value1.54B
Revenue4.59M
Net income-45.02M
Gross profit—
Free cash flow-34.53M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out73.02M
Employees264
ListedFri, Apr 28, 2017
Free float45.96M
Float %62.3%
Short interest4.1M
Days to cover7.6d
Short volume75.1%
Squeeze score78 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.62 vs −$0.56
Last surprise-10.7% miss
Setup gradeC
Conviction51 / 100
Pattern quality—
Tech rank48.0 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance27.28
Support21.72
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in ZYME
No recent disclosed trades by Congress in ZYME. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ZYME · 8 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Schneider Paul R EVP, General Counsel · Stock Option (Right to Buy) · 2026-05-13 | Grant | 178K | $0 | 2026-05-13 | 2026-05-15 |
Schneider Paul R EVP, General Counsel · Restricted Stock Unit · 2026-05-13 | Grant | 119K | $0 | 2026-05-13 | 2026-05-15 |
Schayowitz Adam See Remarks · Performance Stock Unit · 2026-04-09 | Grant | 76K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Stock Option (Right to Buy) · 2026-04-09 | Grant | 70K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Restricted Stock Unit · 2026-04-09 | Grant | 47K | $0 | 2026-04-09 | 2026-04-10 |
Schayowitz Adam See Remarks · Stock Option (Right to Buy) · 2026-04-09 | Grant | 70K | $0 | 2026-04-09 | 2026-04-10 |
Platshon Scott EVP, Chief Business Officer · Performance Stock Unit · 2026-04-09 | Grant | 76K | $0 | 2026-04-09 | 2026-04-10 |
Schayowitz Adam See Remarks · Restricted Stock Unit · 2026-04-09 | Grant | 47K | $0 | 2026-04-09 | 2026-04-10 |
SEC filings
EDGAR filings in ZYME · 3 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.